文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.

作者信息

Pathangey Latha B, McCurry Dustin B, Gendler Sandra J, Dominguez Ana L, Gorman Jessica E, Pathangey Girish, Mihalik Laurie A, Dang Yushe, Disis Mary L, Cohen Peter A

机构信息

Department of Biochemistry and Molecular Biology, Mayo Clinic, Scottsdale, AZ, USA.

Department of Immunology, Mayo Clinic, Scottsdale, AZ, USA.

出版信息

Oncotarget. 2017 Feb 14;8(7):10785-10808. doi: 10.18632/oncotarget.13911.


DOI:10.18632/oncotarget.13911
PMID:27974697
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5355224/
Abstract

Effective adoptive immunotherapy has proved elusive for many types of human cancer, often due to difficulties achieving robust expansion of natural tumor-specific T-cells from peripheral blood. We hypothesized that antigen-driven T-cell expansion might best be triggered in vitro by acute activation of innate immunity to mimic a life-threatening infection. Unfractionated peripheral blood mononuclear cells (PBMC) were subjected to a two-step culture, first synchronizing their exposure to exogenous antigens with aggressive surrogate activation of innate immunity, followed by γ-chain cytokine-modulated T-cell hyperexpansion. Step 1 exposure to GM-CSF plus paired Toll-like receptor agonists (resiquimod and LPS), stimulated abundant IL-12 and IL-23 secretion, as well as upregulated co-stimulatory molecules and CD11c expression within the myeloid (CD33+) subpopulation. Added synthetic long peptides (>20aa) derived from widely expressed oncoproteins (MUC1, HER2/neu and CMVpp65), were reliably presented to CD4+ T-cells and cross-presented to CD8+ T-cells. Both presentation and cross-presentation demonstrated proteasomal and Sec61 dependence that could bypass the endoplasmic reticulum. Step 2 exposure to exogenous IL-7 or IL-7+IL-2 produced selective and sustained expansion of both CD4+ and CD8+ peptide-specific T-cells with a predominant interferon-γ-producing T1-type, as well as the antigen-specific ability to lyse tumor targets. Other γ-chain cytokines and/or combinations were initially proliferogenic, but followed by a contractile phase not observed with IL-7 or IL-7+IL-2. Regulatory T-cells were minimally propagated under these culture conditions. This mechanistically rational culture sequence, effective even for unvaccinated donors, enables rapid preparation of T-cells recognizing tumor-associated antigens expressed by the majority of human cancers, including pancreatic cancers, breast cancers and glioblastomas.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/56033ea0cb61/oncotarget-08-10785-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/4e17107c24af/oncotarget-08-10785-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/74ad8ef0a58d/oncotarget-08-10785-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/751b7a49a56e/oncotarget-08-10785-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/fefb795cf3d5/oncotarget-08-10785-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/442f8203d5ee/oncotarget-08-10785-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/70772de70b4a/oncotarget-08-10785-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/e44526b36c3f/oncotarget-08-10785-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/56033ea0cb61/oncotarget-08-10785-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/4e17107c24af/oncotarget-08-10785-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/74ad8ef0a58d/oncotarget-08-10785-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/751b7a49a56e/oncotarget-08-10785-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/fefb795cf3d5/oncotarget-08-10785-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/442f8203d5ee/oncotarget-08-10785-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/70772de70b4a/oncotarget-08-10785-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/e44526b36c3f/oncotarget-08-10785-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6935/5355224/56033ea0cb61/oncotarget-08-10785-g008.jpg

相似文献

[1]
Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.

Oncotarget. 2017-2-14

[2]
Targeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cells.

J Immunol. 2014-7-15

[3]
Role of the cytokine environment and cytokine receptor expression on the generation of functionally distinct dendritic cells from human monocytes.

Eur J Immunol. 2008-3

[4]
Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.

Clin Immunol. 2006-4

[5]
Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.

J Leukoc Biol. 1997-4

[6]
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.

Clin Cancer Res. 2007-3-15

[7]
Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.

Cancer Res. 2001-11-1

[8]
Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Clin Exp Immunol. 2015-11

[9]
Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.

BMC Immunol. 2013-9-22

[10]
Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.

Hum Immunol. 2004-2

引用本文的文献

[1]
Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients.

JCI Insight. 2025-1-23

[2]
A therapeutic regimen using neoantigen-specific TCR-T cells for HLA-A*2402-positive solid tumors.

EMBO Mol Med. 2025-2

[3]
Combining iRGD with HuFOLactis enhances antitumor potency by facilitating immune cell infiltration and activation.

Hum Vaccin Immunother. 2024-12-31

[4]
Efficacy of MAGE-A4 long peptide as a universal immunoprevention cancer vaccine.

Cancer Cell Int. 2024-7-3

[5]
Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy.

Nat Commun. 2022-12-3

[6]
Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients.

BMC Cancer. 2021-10-15

[7]
Multipeptide stimulated PBMCs generate T/T for adoptive cell therapy in multiple myeloma.

Oncotarget. 2021-9-28

[8]
Differentiation and Regulation of T Cells: A Balancing Act for Cancer Immunotherapy.

Front Immunol. 2021

[9]
Immunomodulatory Therapeutic Proteins in COVID-19: Current Clinical Development and Clinical Pharmacology Considerations.

J Clin Pharmacol. 2020-9-8

[10]
Vaccines as an Integral Component of Cancer Immunotherapy.

JAMA. 2018-12-4

本文引用的文献

[1]
Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.

Oncotarget. 2016-7-12

[2]
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma.

Immunity. 2016-6-21

[3]
Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

Blood. 2016-7-21

[4]
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.

Nat Rev Drug Discov. 2016-3-11

[5]
Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients.

Oncotarget. 2016-3-22

[6]
MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.

PLoS One. 2016-1-20

[7]
Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP.

Oncotarget. 2015-8-21

[8]
Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients.

J Neurooncol. 2015-11

[9]
The translocon protein Sec61 mediates antigen transport from endosomes in the cytosol for cross-presentation to CD8(+) T cells.

Immunity. 2015-5-12

[10]
A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.

Clin Cancer Res. 2015-3-1

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索